Detalles de la búsqueda
1.
Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Mol Cell Proteomics
; 11(7): M111.013243, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22442257
2.
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
Biochem Biophys Res Commun
; 425(4): 711-6, 2012 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-22842455
3.
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Cancer Sci
; 102(3): 614-21, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21205082
4.
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Anticancer Drugs
; 22(5): 454-62, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21389848
5.
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Cancer Res
; 67(17): 8014-21, 2007 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17804712
6.
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Clin Cancer Res
; 12(5): 1630-8, 2006 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16533791
7.
(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.
J Med Chem
; 49(2): 716-26, 2006 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-16420057
8.
YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation.
Cancer Lett
; 238(1): 119-27, 2006 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-16095812
9.
Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Bioorg Med Chem
; 14(6): 1827-37, 2006 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16290163
10.
Stereoselective synthesis of methyl (Z)-(4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene)acetate using a dianion Horner-Wadsworth-Emmons reagent.
Chem Pharm Bull (Tokyo)
; 53(5): 589-90, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15863939
11.
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.
Biol Pharm Bull
; 28(11): 2096-101, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16272696
12.
Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
Chem Pharm Bull (Tokyo)
; 53(7): 764-9, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15997131
13.
Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
Chem Pharm Bull (Tokyo)
; 51(9): 1075-80, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12951451
Resultados
1 -
13
de 13
1
Próxima >
>>